John Galvin

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Oncology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Betty K Hamilton, Paul Williams, John Galvin, James Turnbull, Jingbo Yu
Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncology and therapy 12 (3) (2024)
Corey Cutler, Stephanie J Lee, Sally Arai, Marcello Rotta, Behyar Zoghi, Aleksander Lazaryan, Aravind Ramakrishnan, Zachariah DeFilipp, Amandeep Salhotra, Wanxing Chai-Ho, Rohtesh Mehta, Trent Wang, Mukta Arora, Iskra Pusic, Ayman Saad, Nirav N Shah, Sunil Abhyankar, Carlos Bachier, John Galvin, Annie Im, Amelia A Langston, Jane Liesveld, Mark B Juckett, Aaron Logan, Levanto Schachter, Asif Alavi, Dianna Howard, Harlan W Waksal, John Ryan, David Eiznhamer, Sanjay K Aggarwal, Jonathan Ieyoub, Olivier Schueller, Laurie Green, Zhongming Yang, Heidi Krenz, Madan Jagasia, Bruce R Blazar, Steven Pavletic
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood 138 (22) (2022)